AYOXXA Biosystems appoints Dr. Gerald Möller as Chairman of the Board

Company directs its powerful multiplex platform to unlock the power of proteomics in precision medicine

Cologne, September 14th, 2015      
      
AYOXXA Biosystems GmbH, an international biotechnology company, announced that Dr. Gerald Möller has joined the company's supervisory board as an independent board director and chairman of the board. With 40 years of experience in Pharma, Diagnostics and Biotech, Dr. Möller will guide AYOXXA’s strategic expansion from life science research into disease specific applications, where LUNARIS™, AYOXXA’s unique and new multiplexing technology enables researchers in academia and the pharma industry to address the importance of proteomics in discovery and development of new medicines.

In the early commercialization phase AYOXXA’s customers gave very encouraging feedback and have seen how LUNARIS™ multiplex protein quantification platform is helping them to answer important questions about complex diseases and personalized medicine. Rainer Christine comments: “It was a great pleasure for me to be an investor and the chairman of AYOXXA during the company’s early stages. With the launch of its first products, AYOXXA is now entering a new phase. I am thrilled that Dr. Gerald Möller will from now on chair AYOXXA’s board and bring to bear his vast experience and excellent reputation in the field.” Dr. Andreas Schmidt CEO and Co-founder of AYOXXA Biosystems GmbH comments: “I am excited about his commitment as new chairmen and investor of AYOXXA. What we see in genomics will be complemented by better understanding the power of proteomics. With Gerald Möller we found an experienced international leader to take up this challenge together with the board and management of AYOXXA.

“Over the last years I have been active in the fields of genomics and tissue phenomics and supported their important and growing impact in precision medicine. I am excited about the potential of the AYOXXA multiplexing platform which could become a strong vehicle to unlock the power of proteomics in the discovery and development of new diagnostics and therapeutics, both in academia and industry. With the first products moving into the markets it is an optimal time for me to join and help. I am impressed by what the people at AYOXXA have accomplished so far”, says Dr. Gerald Möller.

About Dr. Gerald Möller:       
Dr. Gerald Möller has about 40 years of management experience in the Diagnostic and Pharmaceutical Industries. From 1975-1998 he held several senior management positions in the global organization of Boehringer Mannheim, where he became CEO of the worldwide operating Group in 1995. Following the sale of Boehringer Mannheim to Roche, he became member of Roche’s Executive Committee till December 1998. Moeller was an Investment Advisor to HMB Partners, Switzerland from 2002 to 2014 and an active participant in the international Healthcare/Biotechnology sector serving on the board of many innovative growing companies, most of which were successfully sold to large, global Healthcare firms. He served 5 years on the Board of Illumina Inc. which he left in May 2015. He is Chairman of Morphosys AG in Germany.

Media Contact:    
AYOXXA Biosystems GmbH
Dr. Marion Lammertz
Marketing Manager Communications
Nattermannallee 1
50829 Köln
Phone: +49 (0) 221 222529 41
marion.lammertz@ayoxxa.com

About AYOXXA
AYOXXA Biosystems GmbH, an international biotech company based in Cologne (Germany), Boston (USA) and Singapore, has developed LUNARIS™ the proprietary technology platform for multiplex protein analysis. LUNARIS™ BioChips enable researchers to perform simultaneous detection of multiple biomarkers in very small sample volume. Founded in 2010, AYOXXA is a biotech spin-off company of the National University of Singapore (NUS). Core to the cutting-edge technology is a bead-based method that yields 10,000-fold more data points than a standard immunoassay.
In September 2015, AYOXXA launched LUNARIS™ 6-Plex Cytokine Kits to analyze prominent biomarkers that are important in inflammation and in immune regulation in human and mouse. Together with a sample volume down to 3 µL, an increased assay robustness, and using fluorescence readout, AYOXXA will innovate biomedical research, pharmacological screening and preclinical diagnostics development.

Download Press Release as PDF